307 related articles for article (PubMed ID: 19378293)
21. Development of an immobilized GPR17 receptor stationary phase for binding determination using frontal affinity chromatography coupled to mass spectrometry.
Temporini C; Ceruti S; Calleri E; Ferrario S; Moaddel R; Abbracchio MP; Massolini G
Anal Biochem; 2009 Jan; 384(1):123-9. PubMed ID: 18835238
[TBL] [Abstract][Full Text] [Related]
22. Online magnetic bead based dynamic protein affinity selection coupled to LC-MS for the screening of acetylcholine binding protein ligands.
Pochet L; Heus F; Jonker N; Lingeman H; Smit AB; Niessen WM; Kool J
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(20):1781-8. PubMed ID: 21565564
[TBL] [Abstract][Full Text] [Related]
23. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening.
Toledo-Sherman L; Deretey E; Slon-Usakiewicz JJ; Ng W; Dai JR; Foster JE; Redden PR; Uger MD; Liao LC; Pasternak A; Reid N
J Med Chem; 2005 May; 48(9):3221-30. PubMed ID: 15857128
[TBL] [Abstract][Full Text] [Related]
24. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
Tolonen A; Turpeinen M; Pelkonen O
Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
[TBL] [Abstract][Full Text] [Related]
25. Advances with weak affinity chromatography for fragment screening.
Tsopelas F; Tsantili-Kakoulidou A
Expert Opin Drug Discov; 2019 Nov; 14(11):1125-1135. PubMed ID: 31380703
[No Abstract] [Full Text] [Related]
26. Method for quantitative protein-ligand affinity measurements in compound mixtures.
Annis DA; Shipps GW; Deng Y; Popovici-Müller J; Siddiqui MA; Curran PJ; Gowen M; Windsor WT
Anal Chem; 2007 Jun; 79(12):4538-42. PubMed ID: 17500537
[TBL] [Abstract][Full Text] [Related]
27. Evaluating carbohydrate-protein binding interactions using frontal affinity chromatography coupled to mass spectrometry.
Palcic MM; Zhang B; Qian X; Rempel B; Hindsgaul O
Methods Enzymol; 2003; 362():369-76. PubMed ID: 12968377
[No Abstract] [Full Text] [Related]
28. Biochemical applications of mass spectrometry in pharmaceutical drug discovery.
Geoghegan KF; Kelly MA
Mass Spectrom Rev; 2005; 24(3):347-66. PubMed ID: 15389851
[TBL] [Abstract][Full Text] [Related]
29. Screening for galectin-3 inhibitors from synthetic lacto-N-biose libraries using microscale affinity chromatography coupled to mass spectrometry.
Fort S; Kim HS; Hindsgaul O
J Org Chem; 2006 Sep; 71(19):7146-54. PubMed ID: 16958507
[TBL] [Abstract][Full Text] [Related]
30. Fragment-based ligand discovery.
Fischer M; Hubbard RE
Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
[TBL] [Abstract][Full Text] [Related]
31. An immuno-chemo-proteomics method for drug target deconvolution.
Saxena C; Zhen E; Higgs RE; Hale JE
J Proteome Res; 2008 Aug; 7(8):3490-7. PubMed ID: 18590316
[TBL] [Abstract][Full Text] [Related]
32. Specific affinity extraction method for small molecule-binding proteins.
Mano N; Sato K; Goto J
Anal Chem; 2006 Jul; 78(13):4668-75. PubMed ID: 16808480
[TBL] [Abstract][Full Text] [Related]
33. Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound.
Sakamoto S; Hatakeyama M; Ito T; Handa H
Bioorg Med Chem; 2012 Mar; 20(6):1990-2001. PubMed ID: 22264760
[TBL] [Abstract][Full Text] [Related]
34. Toward high-throughput drug screening on a chip-based parallel affinity separation platform.
Ohlson S; Duong-Thi MD; Bergström M; Fex T; Hansson L; Pedersen L; Guazotti S; Isaksson R
J Sep Sci; 2010 Sep; 33(17-18):2575-81. PubMed ID: 20730836
[TBL] [Abstract][Full Text] [Related]
35. Preparation of photo-cross-linked small molecule affinity matrices for affinity selection of protein targets for biologically active small molecules.
Takayama H; Moriya T; Kanoh N
Methods Mol Biol; 2012; 800():75-83. PubMed ID: 21964783
[TBL] [Abstract][Full Text] [Related]
36. Chemistry-based functional proteomics for drug target deconvolution.
Wang K; Yang T; Wu Q; Zhao X; Nice EC; Huang C
Expert Rev Proteomics; 2012 Jun; 9(3):293-310. PubMed ID: 22809208
[TBL] [Abstract][Full Text] [Related]
37. Solid-phase assays for small molecule screening using sol-gel entrapped proteins.
Lebert JM; Forsberg EM; Brennan JD
Biochem Cell Biol; 2008 Apr; 86(2):100-10. PubMed ID: 18443623
[TBL] [Abstract][Full Text] [Related]
38. Determining the mode of action of bioactive compounds.
Azad MA; Wright GD
Bioorg Med Chem; 2012 Mar; 20(6):1929-39. PubMed ID: 22300885
[TBL] [Abstract][Full Text] [Related]
39. Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment.
Campbell JL; Le Blanc JC
Bioanalysis; 2011 Mar; 3(6):645-57. PubMed ID: 21417733
[TBL] [Abstract][Full Text] [Related]
40. A chemogenomic approach to drug discovery: focus on cardiovascular diseases.
Cases M; Mestres J
Drug Discov Today; 2009 May; 14(9-10):479-85. PubMed ID: 19429507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
